Correction to: Nature Communications https://doi.org/10.1038/s41467-019-12657-w, published online 15 October 2019.
The original HTML and PDF of this Article contained errors in Figs. 3 and 4. All panels for Figures 3 and 4 were inadvertently inverted. This has been corrected in both the HTML and PDF versions of the Article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Michaelis, K.A., Norgard, M.A., Zhu, X. et al. Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat Commun 10, 5257 (2019). https://doi.org/10.1038/s41467-019-13151-z
Published:
DOI: https://doi.org/10.1038/s41467-019-13151-z
This article is cited by
-
Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity
Cancer Immunology, Immunotherapy (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
